Overactive bladder syndrome (OABS) is a chronic condition which is usually treated by anti-cholinergic drugs needing long term continuous treatment which include combination of life style modification, bladder training, behavioural modification and medical therapy. Other treatment options like botulinum toxin intravesically, sacral nerve stimulation, augmentation cystoplasty and urinary diversion are rarely performed.  Study aims efficacy of solifenacin and tolterodine in women with overactive bladder syndrome.

It was a prospective comparative study on 60 patients diagnosed as OABS on history taking, examination and baseline investigations underwent urodynamic study (UDS), OABS Score and Incontinence Impact Questionnaire (IIQ). Subjects were randomised to 2 groups , Group 1 (Solifenacin 5 mg) while Group II (Tolterodine 4 mg) daily for 6 months and were followed up at 1, 3, and 6 months for OABS score, IIQ and any adverse events. UDS was repeated after 6 months. Descriptive statistics such as mean, median, standard deviation and range values were calculated for study characteristics like age, body mass index and duration of symptoms. Continuous variables were tested for normality assumptions using Kolmogrov Smirnov tests, Chi square test or Fisher’s exact test was used for frequencies of categorical variations. A two tailed probability level with p<0.05 was considered for statistical significance. All data analysis were carried out using IBM SPSS statistics for windows version 19.0 New York IBM Corp.

Mean baseline value of OABS score was 8.5±1.87 (group I) and 8.57±1.5 (group II) which reduced to 5.6 (group I) and 5.57 (group II) in 3 months further reducing to 3.13 and 3.8 in 6 months. Baseline Mean IIQ was 12.77±3.88 (group I) and 11.77±2.9 (group II) reducing to 8.17(group I) and 4.67 (group II).
On UDS, baseline detrusor overactivity was 70% (group I) and 73.3% (group II) which reduced to 3.33% (group I) and 6.66% (group II) after 6 months. Baseline Mean Qmax (maximum flow rate) was 31.88±6.68 (group I) and 32.28±5.80 (group II) reducing to 19.60±3.53 (group I) and 18.62±3.21 (group II). Mean T Void (total time to void) at baseline was 33.89±6.87 (group I) and 32.03±5.08 (group II) which increased to 42.91±6.47 (group I) and 36.84±3.78 (group II). Adverse effects was higher in group II as compared to group I (p=0.02).

Both, Solifenacin and Tolterodine are effective for OABS with Solifenacin showing higher increase in T Void and higher reduction in OABS score.

Solifenacin and Tolterodine are effective for OABS with Solifenacin showing higher reduction in OABS score.